精准医学的前景：生物标志物如何塑造胆管癌治疗的未来。 - Suppr

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment.

作者信息

Macias Rocio I R, Rimassa Lorenza, Lamarca Angela

机构信息

Experimental Hepatology and Drug Targeting (HEVEPHARM), IBSAL, University of Salamanca, Salamanca, Spain.

National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Health Institute, Madrid, Spain.

出版信息

Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):457-461. doi: 10.21037/hbsn-23-215. Epub 2023 May 22.

DOI:10.21037/hbsn-23-215

PMID:37351132

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10282684/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9c1/10282684/e16af3dc80a8/hbsn-12-03-457-f1.jpg

相似文献

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment.

Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):457-461. doi: 10.21037/hbsn-23-215. Epub 2023 May 22.

How to incorporate new agents into precise medicine for cholangiocarcinoma?

Am J Cancer Res. 2024 May 15;14(5):2570-2583. doi: 10.62347/NFDL2398. eCollection 2024.

Precision medicine in cholangiocarcinoma.

Transl Gastroenterol Hepatol. 2018 Jul 12;3:40. doi: 10.21037/tgh.2018.07.02. eCollection 2018.

Molecular genetics and targeted therapeutics in biliary tract carcinoma.

World J Gastroenterol. 2016 Jan 28;22(4):1335-47. doi: 10.3748/wjg.v22.i4.1335.

Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.

Expert Opin Investig Drugs. 2021 Apr;30(4):419-427. doi: 10.1080/13543784.2021.1897103. Epub 2021 Mar 7.

The state of therapy modalities in clinic for biliary tract cancer.

Front Biosci (Landmark Ed). 2022 Jun 8;27(6):185. doi: 10.31083/j.fbl2706185.

Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.

Clin Colorectal Cancer. 2019 Jun;18(2):81-90. doi: 10.1016/j.clcc.2019.02.005. Epub 2019 Feb 27.

Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.

Cancer Treat Rev. 2020 Jun;86:101998. doi: 10.1016/j.ctrv.2020.101998. Epub 2020 Mar 12.

Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.

Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211039952. doi: 10.1177/15330338211039952.

Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.

Cancer Lett. 2022 Oct 10;546:215853. doi: 10.1016/j.canlet.2022.215853. Epub 2022 Jul 31.

引用本文的文献

SENP1 promotes p27kip1 nuclear export though enhanced SUMOylation in cholangiocarcinoma leading to increased cell proliferation and chemoresistance.

Int J Mol Med. 2025 Sep;56(3). doi: 10.3892/ijmm.2025.5582. Epub 2025 Jul 19.

MDM2 as a therapeutic target in advanced biliary tract cancers.

Oncologist. 2025 May 8;30(5). doi: 10.1093/oncolo/oyaf094.

Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6.

Sci Rep. 2024 Nov 29;14(1):29661. doi: 10.1038/s41598-024-81392-0.

liver resection and auto-transplantation and special systemic therapy in perihilar cholangiocarcinoma treatment.

World J Gastrointest Surg. 2024 Mar 27;16(3):635-640. doi: 10.4240/wjgs.v16.i3.635.

Advances in targeted therapy of cholangiocarcinoma.

Ann Med. 2024 Dec;56(1):2310196. doi: 10.1080/07853890.2024.2310196. Epub 2024 Feb 15.

本文引用的文献

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.

Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.

N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.

J Hepatol. 2023 Mar;78(3):614-626. doi: 10.1016/j.jhep.2022.11.030. Epub 2022 Dec 15.

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.

Lancet Oncol. 2022 Dec;23(12):1558-1570. doi: 10.1016/S1470-2045(22)00621-0. Epub 2022 Nov 16.

Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe.

Ann Oncol. 2022 Nov;33(11):1200-1202. doi: 10.1016/j.annonc.2022.07.006. Epub 2022 Aug 1.

Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.

J Hepatol. 2022 Nov;77(5):1359-1372. doi: 10.1016/j.jhep.2022.05.043. Epub 2022 Jun 20.

Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions.

Gut. 2022 Aug;71(8):1669-1683. doi: 10.1136/gutjnl-2022-327099. Epub 2022 May 17.

Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review.

Hepatobiliary Surg Nutr. 2022 Apr;11(2):253-266. doi: 10.21037/hbsn-20-475.

Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.

J Hepatol. 2022 May;76(5):1109-1121. doi: 10.1016/j.jhep.2021.12.010. Epub 2022 Feb 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment.

作者信息

Macias Rocio I R, Rimassa Lorenza, Lamarca Angela

机构信息

Experimental Hepatology and Drug Targeting (HEVEPHARM), IBSAL, University of Salamanca, Salamanca, Spain.

National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Health Institute, Madrid, Spain.

出版信息

Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):457-461. doi: 10.21037/hbsn-23-215. Epub 2023 May 22.

DOI:10.21037/hbsn-23-215

PMID:37351132

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10282684/

Abstract

摘要

相似文献

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment.

Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):457-461. doi: 10.21037/hbsn-23-215. Epub 2023 May 22.

How to incorporate new agents into precise medicine for cholangiocarcinoma?

Am J Cancer Res. 2024 May 15;14(5):2570-2583. doi: 10.62347/NFDL2398. eCollection 2024.

Precision medicine in cholangiocarcinoma.

Transl Gastroenterol Hepatol. 2018 Jul 12;3:40. doi: 10.21037/tgh.2018.07.02. eCollection 2018.

Molecular genetics and targeted therapeutics in biliary tract carcinoma.

World J Gastroenterol. 2016 Jan 28;22(4):1335-47. doi: 10.3748/wjg.v22.i4.1335.

Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.

Expert Opin Investig Drugs. 2021 Apr;30(4):419-427. doi: 10.1080/13543784.2021.1897103. Epub 2021 Mar 7.

The state of therapy modalities in clinic for biliary tract cancer.

Front Biosci (Landmark Ed). 2022 Jun 8;27(6):185. doi: 10.31083/j.fbl2706185.

Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.

Clin Colorectal Cancer. 2019 Jun;18(2):81-90. doi: 10.1016/j.clcc.2019.02.005. Epub 2019 Feb 27.

Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.

Cancer Treat Rev. 2020 Jun;86:101998. doi: 10.1016/j.ctrv.2020.101998. Epub 2020 Mar 12.

Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.

Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211039952. doi: 10.1177/15330338211039952.

Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.

Cancer Lett. 2022 Oct 10;546:215853. doi: 10.1016/j.canlet.2022.215853. Epub 2022 Jul 31.

引用本文的文献

SENP1 promotes p27kip1 nuclear export though enhanced SUMOylation in cholangiocarcinoma leading to increased cell proliferation and chemoresistance.

Int J Mol Med. 2025 Sep;56(3). doi: 10.3892/ijmm.2025.5582. Epub 2025 Jul 19.

MDM2 as a therapeutic target in advanced biliary tract cancers.

Oncologist. 2025 May 8;30(5). doi: 10.1093/oncolo/oyaf094.

Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6.

Sci Rep. 2024 Nov 29;14(1):29661. doi: 10.1038/s41598-024-81392-0.

liver resection and auto-transplantation and special systemic therapy in perihilar cholangiocarcinoma treatment.

World J Gastrointest Surg. 2024 Mar 27;16(3):635-640. doi: 10.4240/wjgs.v16.i3.635.

Advances in targeted therapy of cholangiocarcinoma.

Ann Med. 2024 Dec;56(1):2310196. doi: 10.1080/07853890.2024.2310196. Epub 2024 Feb 15.

本文引用的文献

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.

Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.

Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.

N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.

J Hepatol. 2023 Mar;78(3):614-626. doi: 10.1016/j.jhep.2022.11.030. Epub 2022 Dec 15.

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.

Lancet Oncol. 2022 Dec;23(12):1558-1570. doi: 10.1016/S1470-2045(22)00621-0. Epub 2022 Nov 16.

Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe.

Ann Oncol. 2022 Nov;33(11):1200-1202. doi: 10.1016/j.annonc.2022.07.006. Epub 2022 Aug 1.

Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.

J Hepatol. 2022 Nov;77(5):1359-1372. doi: 10.1016/j.jhep.2022.05.043. Epub 2022 Jun 20.

Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions.

Gut. 2022 Aug;71(8):1669-1683. doi: 10.1136/gutjnl-2022-327099. Epub 2022 May 17.

Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review.

Hepatobiliary Surg Nutr. 2022 Apr;11(2):253-266. doi: 10.21037/hbsn-20-475.

Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.

J Hepatol. 2022 May;76(5):1109-1121. doi: 10.1016/j.jhep.2021.12.010. Epub 2022 Feb 12.

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献